Publication: Agudeza visual como factor pronóstico en pacientes con DMAE húmeda
Loading...
Official URL
Full text at PDC
Publication Date
2021-06
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
UCM
Citations
Exportar
Abstract
Objetivo: Evaluar si la agudeza visual en el momento del tratamiento (AV pretratamiento) puede ser un factor pronóstico del resultado obtenido tras el tratamiento en pacientes con Degeneración Macular Asociada a la Edad (DMAE) tratados con Eylea (Aflibercept).
Material y métodos: Se realizó un estudio retrospectivo compuesto por 131 ojos de 116 pacientes con DMAE húmeda de la Clínica Oftalmológica Miranza IOA de Madrid donde todo ellos fueron tratados con Eylea (Aflibercept). Los pacientes se dividieron en tres grupos según la agudeza visual que tenían antes de iniciar el tratamiento y se estudió su evolución durante un año (grupo 1: pacientes con AV comprendidas entre 0 y 0.25 logMAR, grupo 2: pacientes con AV comprendidas entre 0.25 y 0.75 logMAR y grupo 3: pacientes con AV comprendidas entre 0.75 y 1.3 logMAR). También se analizó la influencia del número de inyecciones en la AV de los pacientes.
Resultados: La edad media de los pacientes era de 76.44 ± 10.00 años. Se encontró que la AV media de los pacientes al finalizar el año del estudio es mejor que la AV media inicial, siendo esta diferencia estadísticamente significativa. En pacientes que partían de una peor AV (grupo 3) se observaron diferencias estadísticamente significativas (pvalor < 0.05) entre la AV inicial y la AV final, al igual que en el grupo 2. En el grupo 1 (pacientes con mejor AV inicial) no se observaron diferencias estadísticamente significativas (p-valor = 0.138) entre ambas agudezas visuales. Se observó que los pacientes con peor AV pretratamiento mejoraron más que los pacientes con mejor AV previa. La relación entre el número de inyecciones administradas a los pacientes y su AV previa al tratamiento fue estadísticamente significativa (p-valor < 0.05).
Conclusiones: En general, los pacientes tratados con Eylea mejoran su AV tras un año de tratamiento, siendo los pacientes con peor AV inicial los que más mejoran, por lo que la AV puede utilizarse como factor pronóstico en el tratamiento de la DMAE húmeda con Eylea. El número de inyecciones intravítreas del fármaco no influye en la mejora o el empeoramiento de la AV de los pacientes.
Purpose: To evaluate whether visual acuity at the time of treatment (pretreatment VA) can be a prognostic factor for the results obtained after treatment in patients with AgeRelated Macular Degeneration (AMD) treated with Eylea (Aflibercept). Material and method: A retrospective study was carried out consisting of 131 eyes of 116 patients with wet AMD at the Miranza IOA Ophthalmology Clinic in Madrid, where all of them were treated with Eylea (Aflibercept). The patients were divided into three groups according to the visual acuity before starting the treatment and their evolution was studied for one year (group 1: patients with VA between 0 and 0.25 logMAR, group 2: patients with VA between 0.25 and 0.75 logMAR and group 3: patients with VA between 0.75 and 1.3 logMAR). The influence of the number of injections in the VA of the patients was also analyzed. Results: The mean age of the patients was 76.44 ± 10.00 years. The mean VA of the patients at the end of the study year was found to be better than the initial mean VA, being this difference statistically significant. In patients starting from a worse VA (group 3) statistically significant differences (p-value < .05) were observed between both visual acuities. Patients with worse pretreatment VA were observed to improve more than patients with better previous VA. The relationship between the number of injections and the pretreatment VA was statistically significant (p-value < 0.05). Conclusions: Patients treated with Eylea improve their VA after one-year of treatment, with patients with worse initial VA improving the most, so VA can be used as a prognostic factor in the treatment of wet AMD with Eylea. The number of intravitreal injections of the drug does not influence the improvement or worsening of VA in patients.
Purpose: To evaluate whether visual acuity at the time of treatment (pretreatment VA) can be a prognostic factor for the results obtained after treatment in patients with AgeRelated Macular Degeneration (AMD) treated with Eylea (Aflibercept). Material and method: A retrospective study was carried out consisting of 131 eyes of 116 patients with wet AMD at the Miranza IOA Ophthalmology Clinic in Madrid, where all of them were treated with Eylea (Aflibercept). The patients were divided into three groups according to the visual acuity before starting the treatment and their evolution was studied for one year (group 1: patients with VA between 0 and 0.25 logMAR, group 2: patients with VA between 0.25 and 0.75 logMAR and group 3: patients with VA between 0.75 and 1.3 logMAR). The influence of the number of injections in the VA of the patients was also analyzed. Results: The mean age of the patients was 76.44 ± 10.00 years. The mean VA of the patients at the end of the study year was found to be better than the initial mean VA, being this difference statistically significant. In patients starting from a worse VA (group 3) statistically significant differences (p-value < .05) were observed between both visual acuities. Patients with worse pretreatment VA were observed to improve more than patients with better previous VA. The relationship between the number of injections and the pretreatment VA was statistically significant (p-value < 0.05). Conclusions: Patients treated with Eylea improve their VA after one-year of treatment, with patients with worse initial VA improving the most, so VA can be used as a prognostic factor in the treatment of wet AMD with Eylea. The number of intravitreal injections of the drug does not influence the improvement or worsening of VA in patients.
Description
Curso 2020-2021